0 citations
New and established tyrosine kinase inhibitors for chronic myeloidleukemia
Drugs of today2012Vol. 48(9), pp. 601–601
Citations Over TimeTop 20% of 2012 papers
Abstract
Chronic myeloid leukemia (CML) is an uncommon malignancy, the treatment and prognosis of which have dramatically shifted over the last decade. Characterized by a translocation between chromosomes 9 and 22, known as the Philadelphia chromosome, small-molecule tyrosine kinase inhibitors (TKIs) targeted against the oncogenic BCR-ABL fusion protein have changed this once fatal disease into the model of targeted therapy. This article will review the pharmacological and clinical data supporting the use of imatinib and the second-generation TKIs dasatinib and nilotinib, and the novel TKIs bosutinib and ponatinib.
Related Papers
- → Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis(2015)91 cited
- → Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells(2018)60 cited
- → Incidence of cardiovascular events in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors(2021)8 cited
- → Dasatinib, Nilotinib, Bosutinib, Ponatinib, and Other TKIs(2017)1 cited
- → Molecular targeting agents and cardiovascular adverse events(2018)